Third Party Research Study Demonstrates Pluristem's PLX-PAD Cells' Safety in Human Lung Models of Pulmonary Hypertension

Third Party Research Study Demonstrates Pluristem's PLX-PAD Cells' Safety in
Human Lung Models of Pulmonary Hypertension

Findings Presented at ISHLT Meeting in Montreal

HAIFA, Israel, April 29, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc.
(Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell
therapies, announced today that independent researchers from the Queensland
Lung Transplant Service at the University of Queensland, Australia
demonstrated that following infusion of Pluristem's PLX (Placental eXpanded)
cells in a human lung model of pulmonary arterial hypertension (PAH), blood
flows were maintained and no adverse hemodynamic effects were noted.

The findings were presented on April 25, 2013 at the 33rd Annual Meeting and
Scientific Sessions of the International Society of Heart and Lung
Transplantation (ISHLT) in Montreal, Canada. The presentation and poster
entitled "Safety of a Mesenchymal-like Adherent Stromal Cell (PLX-PAD) in a
Human Model of Pulmonary Arterial Hypertension (PAH)" are available at
Pluristem's website: for the next 30 days.

Zami Aberman, Pluristem's Chairman and CEO, stated, "We are pleased that
independent researchers were able to demonstrate the safety of our PLX-PAD
cells in this unique human lung model designed to bridge the gap between data
obtained from animals and data needed to commence human studies. We look
forward to the initiation of Phase I human studies for this important

On June 20, 2011 United Therapeutics and Pluristem entered into a licensing
agreement pursuant to which United Therapeutics will develop, market and sell
Pluristem's PLX-PAD cells for PAH.

About the Study:

Daniel C. Chambers MD et. al. from Prince Charles Hospital and the University
of Queensland, Australia induced pulmonary hypertension in four human lungs
that had been declined for transplantation. Supra-therapeutic doses of
Pluristem's PLX-PAD cells were then infused over 15 minutes directly into the
pulmonary artery. Pulmonary vascular resistance stabilized during and for the
hour post PLX-PAD infusion without adverse hemodynamic manifestations. The
authors concluded they have demonstrated the acute hemodynamic safety of
supra-therapeutic doses of PLX-PAD cells in an ex vivo model of pulmonary
arterial hypertension.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell
therapies. The Company's patented PLX (PLacental eXpanded) cells are a drug
delivery platform that releases a cocktail of therapeutic proteins in response
to a host of local and systemic inflammatory and ischemic diseases. PLX cells
are grown using the company's proprietary 3D micro-environmental technology
and are an "off-the-shelf" product that requires no tissue matching prior to

Pluristem has a strong intellectual property position, company-owned GMP
certified manufacturing and research facilities, strategic relationships with
major research institutions and a seasoned management team. For more
information visit, the content of which is not part of this
press release.

The Pluristem Therapeutics Inc. logo is available at

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995 and federal securities laws. For example, when we say that we look
forward to the initiation of Phase I human studies for this important
indication, we are using forward-looking statements. These forward-looking
statements and their implications are based on the current expectations of the
management of Pluristem only, and are subject to a number of factors and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. The following factors, among
others, could cause actual results to differ materially from those described
in the forward-looking statements: changes in technology and market
requirements; we may encounter delays or obstacles in launching and/or
successfully completing our clinical trials; our products may not be approved
by regulatory agencies, our technology may not be validated as we progress
further and our methods may not be accepted by the scientific community; we
may be unable to retain or attract key employees whose knowledge is essential
to the development of our products; unforeseen scientific difficulties may
develop with our process; our products may wind up being more expensive than
we anticipate; results in the laboratory may not translate to equally good
results in real surgical settings; results of preclinical studies may not
correlate with the results of human clinical trials; our patents may not be
sufficient; our products may harm recipients; changes in legislation;
inability to timely develop and introduce new technologies, products and
applications; loss of market share and pressure on pricing resulting from
competition, which could cause the actual results or performance of Pluristem
to differ materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, Pluristem undertakes no
obligation to publicly release any revisions to these forward-looking
statements to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. For a more detailed
description of the risks and uncertainties affecting Pluristem, reference is
made to Pluristem's reports filed from time to time with the Securities and
Exchange Commission.

CONTACT: Pluristem Therapeutics Inc.:
         William Prather R.Ph., M.D. Sr. VP Corporate Development
         Daya Lettvin
         Investor & Media Relations Director

Pluristem Therapeutics Inc. Logo
Press spacebar to pause and continue. Press esc to stop.